TTR and amyloidosis: Doxycycline + TUDCA Endpoint: safety/efficacyPhase 2:single center, non-randomized, open-label, prospective study followed by 6 months withdrawal to evaluate efficacy, tolerability, safety, pharmacokinetics of TUDCA in TTR Amyloidosis